Bachrodt Amy
SEC insider (Form 3/4/5 filer). CIK 0002050422. Chief Financial Officer at Lycia Therapeutics, Inc. (LYCA) and 1 other issuer. 29 reported Form 4/5 transactions since Sep 2024; latest on Aug 11, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Bachrodt Amy has filed insider reports for
- Lycia Therapeutics, Inc. (LYCA): Officer, 10% Owner, Chief Financial Officer
- Maze Therapeutics, Inc. (MAZE): Officer, SVP, Finance
Bachrodt Amy
CIK: 0002050422
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (29 total)
- Aug 11, 2026LYCA
Lycia Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
399.7K shares- - Apr 1, 2026MAZE
Maze Therapeutics, Inc.
SaleDirect300 shares at avg. $30.34$9K - Apr 1, 2026MAZE
Maze Therapeutics, Inc.
SaleDirect2.2K shares at avg. $29.32$65K - Apr 1, 2026MAZE
Maze Therapeutics, Inc.
ExerciseDirect2.5K shares at avg. $10.42$26K - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
AwardDirectRestricted Stock Units
16K shares- - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
32K shares- - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
SaleDirect3.7K shares at avg. $45.47$168K - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
SaleDirect1.3K shares at avg. $44.44$58K - Mar 2, 2026MAZE
Maze Therapeutics, Inc.
ExerciseDirect5K shares at avg. $10.42$52K - Feb 2, 2026MAZE
Maze Therapeutics, Inc.
ExerciseDirect156 shares at avg. $10.42$2K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 11, 2026 |  LYCA Lycia Therapeutics, Inc. | Award Stock Option (Right to Buy) | 399,746 | - | - | Direct |
| Apr 1, 2026 |  MAZE Maze Therapeutics, Inc. | Sale | 300 | $30.34 | $9,101 | Direct |
| Apr 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale | 2,200 | $29.32 | $64,510 | Direct |
| Apr 1, 2026 | MAZE Maze Therapeutics, Inc. | Exercise | 2,500 | $10.42 | $26,050 | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Award Restricted Stock Units | 16,000 | - | - | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Award Stock Option (Right to Buy) | 32,000 | - | - | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale | 3,700 | $45.47 | $168,237 | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale | 1,300 | $44.44 | $57,774 | Direct |
| Mar 2, 2026 | MAZE Maze Therapeutics, Inc. | Exercise | 5,000 | $10.42 | $52,100 | Direct |
| Feb 2, 2026 | MAZE Maze Therapeutics, Inc. | Exercise | 156 | $10.42 | $1,626 | Direct |
1-10 of 29 transactions